<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Simultaneous control of blood <z:chebi fb="105" ids="17234">glucose</z:chebi> and other risk factors such as <z:hpo ids='HP_0000822'>hypertension</z:hpo> and <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e> is essential for reducing the risk of complications associated with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> (T2DM) </plain></SENT>
<SENT sid="1" pm="."><plain>As relatively few patients with T2DM have their risk factors managed to within the limits recommended by the American <z:mp ids='MP_0002055'>Diabetes</z:mp> Association, American College of Endocrinology or National Cholesterol Education Program Adult Treatment Panel III guidelines, treatment that can simultaneously control more than one risk factor is of therapeutic benefit </plain></SENT>
<SENT sid="2" pm="."><plain>Clinical studies have shown that <z:chebi fb="0" ids="3098">bile acid</z:chebi> sequestrants have <z:chebi fb="105" ids="17234">glucose</z:chebi>-lowering effects in addition to their <z:chebi fb="1" ids="47774">low-density lipoprotein cholesterol</z:chebi>-lowering effects in patients with T2DM </plain></SENT>
<SENT sid="3" pm="."><plain>The <z:chebi fb="0" ids="3098">bile acid</z:chebi> sequestrant colesevelam <z:chebi fb="16" ids="36807">hydrochloride</z:chebi> is approved as an adjunct to antidiabetes therapy for improving glycaemic control in adults with T2DM </plain></SENT>
<SENT sid="4" pm="."><plain>This review examines data from three phase III clinical trials that evaluated the <z:chebi fb="105" ids="17234">glucose</z:chebi>- and <z:chebi fb="23" ids="18059">lipid</z:chebi>-lowering effects of colesevelam when added to the existing antidiabetes treatment regimen of patients with T2DM </plain></SENT>
</text></document>